- Open Access
Correction to: Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons
© The Author(s) 2018
- Received: 14 February 2018
- Accepted: 14 February 2018
- Published: 23 February 2018
The original article was published in Journal of Translational Medicine 2018 16:24
It is unclear whether the reduction in Streptococcus is particularly beneficial in some ME/CFS patients or whether other concurrent microbial shifts are equally or more valuable (i.e., increased Bacteroides and/or reduced Clostridium).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Wallis A, Ball M, Butt H, Lewis DP, McKechnie S, Paull P, Jaa-Kwee A, Bruck D. Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons. J Transl Med. 2018;16:24. https://doi.org/10.1186/s12967-018-1392-z.View ArticlePubMedPubMed CentralGoogle Scholar